REACH3: Phase III Trial of Ruxolitinib vs Best Available Therapy in Steroid-Refractory/Dependent, Chronic GVHD

December 5-8, 2020; Online at
Data from REACH3 shows ruxolitinib significantly improves responses and symptoms at Week 24 in patients with cGVHD, and inadequate steroid response, when compared with BAT.
Format: Microsoft PowerPoint (.ppt)
File Size: 219 KB
Released: December 9, 2020


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Epizyme Inc.
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Dr Jeff Sharman provides expert insight into the optimal treatment combinations in the management of CLL/SLL, from Clinical Care Options (CCO)

Jeff Sharman, MD Released: November 22, 2022

Video featuring an expert discussion of BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Matthew S. Davids, MD, MMSc Anthony Mato, MD, MSCE Jeff Sharman, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Expert slides on nursing care for patients receiving CAR T-cells, including managing acute and long-term toxicities, from Clinical Care Options (CCO)

person default Kathryn Ciccolini, DNP, AGACNP-BC, OCN Linda Ramsdell, MSN, FNP-BC, OCN Released: November 17, 2022

Expert commentary on data from the SOHO 2022 Annual Meeting on BTK inhibitors for CLL and MCL, from Clinical Care Options (CCO)

Christopher R. Flowers, MD, MS Kami Maddocks, MD Released: November 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings